BIVI Makes Leading Pet Vaccines

The Boehringer Ingelheim Vetmedica, Inc. (BIVI) complete line of canine and feline vaccines is time-tested and proved safe and effective. They offer the latest vaccine technology with the most up-to-date protection against major dog and cat diseases. They are some of the most widely used vaccines in U.S. veterinary clinics today.

About Boehringer Ingelheim Vetmedica, Inc.


Founded in 1885, BIVI is a family-owned global company with 44,000 employees worldwide. The company has $1 billion in global animal health sales and ranks in the top five of all animal health companies. Boehringer-Ingelheim focuses on human and animal health, and markets products in 152 countries with more than $17 billion net sales.

BIVI leaders in research and development


BIVI operates cutting-edge vaccine research centers in St. Joseph in Missouri and Ames and Sioux Center in Iowa. These centers are instrumental in innovative delivery technology.


World-class manufacturing processes


BIVI works continuously to improve its world-class manufacturing process through technical expertise and state-of-the-art manufacturing practices. Biological production meets all global standards in manufacturing bacterial and viral vaccines, and produces more than 120 high-quality antigens placed in innovative products for dogs, cats, pigs, cattle and horses. Currently BIVI produces over 800 million doses of vaccine per year and estimates the number of doses will increase to a billion by 2015.


The five pillars in the fountain represent the five continents where BIVI conducts business. (Above: Global Headquarters in Ingelheim, Germany.)